Patent analysis for dapagliflozin
WANG Xing
Abstract：Dapagliflozin is a highly selective sodium-dependent glucose transporters 2(SGLT-2)inhibitor,and can be used as a single agent for glycemic control in adult patients with type 2 diabetes mellitus.To help developers understand the development trends of the drug,the body of development and the protection situation in China,statistical analysis of dapagliflozin-related patent application scenarios is performed herein from the perspective of patent application trends,regional distribution,important applicants,in order to provide advice on technological development and intellectual property strategies to domestically relevant pharmaceutical companies.
Keywords：dapagliflozintype 2 diabetessodium-dependent glucose transporters 2 inhibitorspatent analysis
Publication Date：2024-11-15
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 2209-2213 )